ecopipam has been researched along with Lesch-Nyhan Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chipkin, R; Jinnah, HA; Khasnavis, T; Nyhan, WL; Reiner, G; Sommerfeld, B | 1 |
| Chipkin, R; Jinnah, HA; Khasnavis, T; Puig, JG; Sommerfeld, B; Torres, RJ | 1 |
| Seifert, R | 1 |
2 trial(s) available for ecopipam and Lesch-Nyhan Syndrome
| Article | Year |
|---|---|
A clinical trial of safety and tolerability for the selective dopamine D1 receptor antagonist ecopipam in patients with Lesch-Nyhan disease.
Topics: Adolescent; Adult; Benzazepines; Child; Dopamine Antagonists; Humans; Lesch-Nyhan Syndrome; Male; Middle Aged; Receptors, Dopamine D1; Self-Injurious Behavior; Treatment Outcome; Young Adult | 2016 |
A double-blind, placebo-controlled, crossover trial of the selective dopamine D1 receptor antagonist ecopipam in patients with Lesch-Nyhan disease.
Topics: Adolescent; Benzazepines; Child; Cross-Over Studies; Dopamine Antagonists; Double-Blind Method; Humans; Lesch-Nyhan Syndrome; Male; Sample Size; Treatment Outcome; Young Adult | 2016 |
1 other study(ies) available for ecopipam and Lesch-Nyhan Syndrome
| Article | Year |
|---|---|
Towards rational drug treatment of Lesch-Nyhan disease.
Topics: Benzazepines; Clinical Trials, Phase II as Topic; Cross-Over Studies; Dopamine Antagonists; Humans; Lesch-Nyhan Syndrome; Receptors, Dopamine D2; Sample Size; Treatment Failure | 2016 |